These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21078047)

  • 21. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 25. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
    Bostwick DG
    Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy.
    Stock RG; Cesaretti JA; Hall SJ; Stone NN
    BJU Int; 2009 Dec; 104(11):1631-6. PubMed ID: 19493260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
    Wilkinson S; Chodak G
    Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.
    Liebertz C; Fox P
    Clin J Oncol Nurs; 2006 Jun; 10(3):361-6. PubMed ID: 16789581
    [No Abstract]   [Full Text] [Related]  

  • 34. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D; Giannakopoulos X; Charalabopoulos K; Sofikitis N
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A; Penson D; Dewilde S; Kleinman L
    Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Hara et al.: Decline of the red cell blood count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor 1 and erythropoesis. (Urology 2010;75:1441-1445).
    Colloca G; Venturino A; Vitucci P
    Urology; 2010 Oct; 76(4):1020. PubMed ID: 20932425
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
    Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
    Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.